RVMDW — Revolution Medicines, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1628171 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -505,132,000 | -644,371,000 | 4,323,270,000 | 815,435,000 | 1,717,032,000 |
| Mar 2026 | 0 | — | -445,222,000 | -453,816,000 | 2,253,737,000 | 440,939,000 | 753,820,000 |
| Dec 2025 | 0 | — | -361,626,000 | -364,892,000 | 2,354,508,000 | 383,745,000 | 723,211,000 |
| Sep 2025 | 0 | — | -315,269,000 | -305,206,000 | 2,251,920,000 | 217,442,000 | 655,016,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,577,198,000
Investing CF
$-1,213,709,000
Financing CF
$3,262,040,000
CapEx
$-10,636,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-3,967,289,000
Inventory
—
Receivables
$0
ST Investments
$3,122,534,000
EBIT TTM
$-1,708,943,000
Pretax Income TTM
$-1,768,285,000
Interest Exp TTM
$59,342,000
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,182,369,000 | -1,131,301,000 | 2,354,508,000 | 723,211,000 | 1,631,297,000 | -897,741,000 |
| Dec 2024 | 0 | -689,524,000 | -600,093,000 | 2,558,301,000 | 293,097,000 | 2,265,204,000 | -557,436,000 |
| Dec 2023 | 11,580,000 | -487,185,000 | -436,367,000 | 2,061,705,000 | 235,511,000 | 1,826,194,000 | -350,572,000 |
| Dec 2022 | 35,380,000 | -258,279,000 | -248,705,000 | 811,930,000 | 126,742,000 | 685,188,000 | -224,401,000 |
TTM Snapshot
Revenues TTM
$-5,407,000
NetIncome TTM
$-1,371,701,000
OpCashFlow TTM
—
Assets (Latest)
$2,253,737,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $224.29B | $414.87 | — |
| GILD | GILEAD SCIENCES, INC. | $187.44B | $151.17 | — |
| MRNA | Moderna, Inc. | $89.83B | $225.00 | — |
| ARGX | ARGENX SE | $51.31B | $825.03 | — |
| RVMD | Revolution Medicines, Inc. | $40.67B | $189.76 | — |
News headlines (Yahoo Finance, 1h cache)
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts
2026-10-09 15:18 · Yahoo
Revolution Medicines CEO on Defeating the RAS Gene
2026-10-07 21:45 · Yahoo
First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
2026-10-07 04:27 · Yahoo
Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
2026-10-06 20:34 · Yahoo
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
2026-10-05 12:00 · Yahoo
Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
2026-09-28 15:58 · Yahoo
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
2026-09-28 12:00 · Yahoo
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
2026-09-25 09:42 · Yahoo
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
2026-09-25 02:35 · Yahoo
Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
2026-09-23 06:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.